IT’S A GO! NF’s NEXT BIG WIN! ?? ??
Today, we make history... again! The FDA has officially approved Gomekli (mirdametinib) - the second-ever FDA-approved treatment for NF1 and the first-ever for adults!
This is a game-changing moment for the NF community. For years, patients and families have waited for more treatment options. Today, that wait gets shorter.
Click here to read more → https://lnkd.in/gAhfGeYR
“We are excited to celebrate the extraordinary milestone of our partners and long-term friends at SpringWorks Therapeutics for the NF community. This FDA approval shows the power of collaboration to advance innovative science for drugs that may otherwise not have been taken forward,” said Annette Bakker, PhD, Chief Executive Officer of the Children’s Tumor Foundation. “When industry, researchers, and organizations like ours driving treatment innovation join forces, scientific progress moves faster, and patients gain access to the therapies they need. Every treatment approval is hard-won, built on research, persistence, and partnership. Today, that work delivers a critical new option for NF patients of all ages.”
Breakthroughs like this don’t happen without YOU. Every patient who participated in a trial, every researcher who pursued new possibilities, and every donor who fueled this work helped make this moment possible. Because of you, NF patients now have another treatment option - and hope for more to come.
Join Us to Celebrate!
To mark this milestone, we’re hosting a special virtual gathering - a chance to come together, celebrate what this means for the NF community, and talk about what’s next.
Date & Time: Friday, Feb. 14, 2025 12PM ET
Register Here: https://lnkd.in/gjUKHbnA
#EndNF Children's Tumor Foundation Europe